OnCore Biopharma Inc. is buying Enantigen Therapeutics Inc. for an undisclosed amount.

Doylestown, Pennsylvania, Enantigen is a pharmaceutical company that is working on developing medicines that inhibit an s-antigen secretion, a process related to immune response, and another that aims to stop capsid assembly, or the production of virus particles.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.